• Start date:
  • 5 April 2019
  • Duration:
  • 2 days
  • Working as:
  • Resident physician, Medical specialist

The retina, as highly specialized creator of sight, is vulnerable to a broad range of monogenic and multifactorial causes of degeneration. As a relatively closed compartment, the eye is on the one hand relatively isolated and immune-privileged from the rest of the body, yet at the same time well-accessible to surgical intervention and a broad range of clinical examinations of its structure and function.  

As such, the retina is at the forefront of development of regenerative therapies such as gene therapy and stem cell therapy. Recently, the first-ever FDA-approved gene therapy was admitted to the market, for RPE65-associated retinal degeneration.

This Boerhaave Course ‘Regenerative Medicine of the Retina’ aims to give a state-of-the-art overview of the current options and progress in regenerative treatments for the retina. In this course, national and international experts in the field will cover the spectrum of developing therapies for retinal degeneration, ranging from AAV-mediated gene therapy, antisense oligonucleotide and CRISPR/Cas treatment, to optogenetics and stem cell therapy. In addition, important aspects of translation to clinical application will be discussed.

Course participants are encouraged to submit their research for a poster and/or rapid fire oral presentation. Prizes will be awarded for the best poster and oral presentations.

We look forward to welcoming you to the beautiful city of Leiden, which is located very centrally, within less than 30 minutes travel distance from Schiphol Airport.

 

Hotel accommodation

Please note that the period of April - May is a very busy touristic seasons because all the bulb fields are flowering.
There will be a big demand of rooms so we advise to make your reservation well in advance.

You can make your reservation by using the following link: https://www.ehp-online.nl/congressubscribe/subscribe?id=3401

  Friday April 5th
12:00 Registration and lunch 
  Chairs: Arthur Bergen, Carel Hoyng, Gré Luyten
13:00 Welcome and opening 
13:05 Adverse immune effects during retinal gene therapy
Dominik Fischer
13:50 Splice modulation therapy using antisense oligonucleotides
Rob Collin 
14:10 Retinal RPE transplantation and prospects for the clinic 
James Bainbridge 
14:55 Tea break and poster viewing 
15:25 Defining clinical endpoints for gene therapy studies
Mays Talib
15:45 Retinal gene therapy vectors
Stylianos Michalakis
16:30 Rapid fire (5 abstracts)
16:50 Closing comments
17:00 Poster session and drinks 
18:30 Dinner 
  Saturday April 6th 
  Chairs: Jan Wijnholds, Camiel Boon, Carel Hoyng
09:00 Opening 
09:05 How to avoid failure in regenerative treatment trials for age-related macular degeneration
Carel Hoyng
09:25 Retinal optogenetics gene therapy
Deniz Dalkara
10:10 Transplantation of iPSC-derived retinal tissue
Céline Koster
10:30 Coffee break and poster viewing
11:00 Gene editing therapy and prospects for the clinic
Manuel Goncalves
11:45 Retinal organoids as a model for hereditary retinal diseases
Philip Wagstaff
12:05 Challenges in retinitis pigmentosa CRB1 gene therapy
Jan Wijnholds
12:25 Lunch/meet the expert 
13:30 Rapid fire (4 abstracts)
13:50 hiPSC vasculature and vessels on chip 
Valeria Orlova
14:35 Practical management of gene therapy/regenerative treatment trials for retinal dystrophies
Dyon Valkenburg
14:55 Closing comments 
LUMC
Albinusdreef 2, 2333 ZA Leiden

Building 1
Lecture Hall 5
Route 558

Registration fee:  € 315,-
Reduction for residents: € 100,-

Dinner on Friday night: € 25,-